The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
Open accessAbstract
The classification of breast cancer into molecular subtypes with distinctive gene expression signatures that predict treatment response and prognosis has ushered in a new era of personalized medicine for this remarkably heterogeneous and deadly disease. Basal-like breast cancer (BLBC) is a particularly aggressive molecular subtype defined by a robust cluster of genes expressed by epithelial cells in the basal or outer layer of the adult mammary gland. BLBC is a major clinical challenge because these tumors are prevalent in young woman, often relapsing rapidly. Additionally, most (but not all) basal-like tumors lack expression of steroid hormone receptors (estrogen receptor and progesterone receptor) and human epidermal growth factor receptor 2, limiting targeted therapeutic options for these predominantly triple-negative breast cancers. This minireview will focus on new insights into the molecular etiology of these poor-prognosis tumors that underlie their intrinsic genomic instability, deregulated cell proliferation and apoptosis, and invasive tumor biology. We will also review ongoing efforts to translate these fundamental insights into improved therapies for women with BLBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“However, the majority of women with TNBC/ BLBC do not have a complete response and are at high risk for early relapse within the first 2–5 yr after treatment, resulting in an overall lower 5-yr survival rate (26, 28, 34, 38).”
BackgroundMicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“Cell proliferation requires progression through the G1 to S cell cycle transition that is negatively regulated by the RB tumor suppressor gene product (78).”
BackgroundIliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · cited 1×
“the majority of which are ER-negative tumors (56, 57).”
BackgroundWang, Y., Cortez, D., Yazdi, P., Neff, N., Elledge, S. J., & Qin, J. (2000) · Genes & Development · doi:10.1101/gad.14.8.927 · Cited by 1,221 · cited 2×
“telangiectasia mutated gene product, Bloom syndrome protein, or Rad50 (60, 61)] might underlie the BRCA1”
BackgroundResistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins
Wang, W. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2159 · Cited by 663
Lung metastasis genes couple breast tumor size and metastatic spread
Minn, A. J., Gupta, G. P., Padua, D., Bos, P., Nguyen, D. X., Nuyten, D., Kreike, B., Zhang, Y., Wang, Y., Ishwaran, H., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701138104 · Cited by 400
Catteau, A., Harris, W. H., Xu, C.-F., & Solomon, E. (1999) · Oncogene · doi:10.1038/sj.onc.1202509 · Cited by 354
Chen, J., Imanaka, N., Chen, J., & Griffin, J. D. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605486 · Cited by 346 · cited 1×
“Developmental EMT pathways may be co-opted by BLBC or stimulated by environmental pressures such as hypoxia (85, 86).”
BackgroundHuang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3633 · Cited by 344 · cited 1×
“Similarly, BLBC cells highly express LYN, a Src family kinase, and are exquisitely sensitive to dasatinib, an inhibitor of Src and Abl kinases (94, 143).”
Background
Cited by
Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies
Nounou, M. I., ElAmrawy, F., Ahmed, N., Abdelraouf, K., Goda, S., & Syed-Sha-Qhattal, H. (2015) · Breast Cancer: Basic and Clinical Research · doi:10.4137/bcbcr.s29420 · Cited by 364
Pathology of triple negative breast cancer
Borri, F., & Granaglia, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.005 · Cited by 300
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance
Xiong, G., Stewart, R. L., Chen, J., Gao, T., Scott, T. L., Samayoa, L. M., O’Connor, K., Lane, A. N., & Xu, R. (2018) · Nature Communications · doi:10.1038/s41467-018-06893-9 · Cited by 274
Cheng, N., Watkins-Schulz, R., Junkins, R. D., David, C. N., Johnson, B. M., Montgomery, S. A., Peine, K. J., Darr, D. B., Yuan, H., McKinnon, K. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120638 · Cited by 260
Platinum-based chemotherapy in triple-negative advanced breast cancer
Villarreal-Garza, C., Khalaf, D., Bouganim, N., Clemons, M., Peña-Curiel, O., Baez-Revueltas, B., Kiss, A., Kassam, F., Enright, K., Verma, S., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3033-4 · Cited by 33
Metadata
- Authors
- Toft, D. J., & Cryns, V. L.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2011-02-01
- Volume
- 25
- Issue
- 2
- Pages
- 199-211
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2084818879
- Cited by
- 161
- References
- 16
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.